Hemispherx Biopharma Inc (NYSE American:HEB) said Thursday that its early access program at the Erasmus Medical Center in the Netherlands, which uses its flagship drug Ampligen for the treatment of pancreatic cancer, has been extended.
The early access program is now approved by Dutch Health authorities until March 9, 2020 to allow for the treatment of pancreatic cancer patients diagnosed with any stage of the disease. The pancreatic cancer patients receive Ampligen as maintenance therapy after completing standard care.
Investors applauded the news, sending Hemispherx shares up 11.6% to $0.19 in afternoon trade Thursday.
In a recent abstract, clinicians at Erasmus found that Ampligen showed positive results in treating pancreatic cancer. Of 26 pancreatic cancer patients treated with Ampligen as maintenance therapy, five patients showed stable disease and two patients exhibited the regression of cancer metastases during treatment.
Hemispherx is dedicated to evaluating Ampligen for the potential treatment of pancreatic cancer, especially in combination with checkpoint blockade therapies.
“We are grateful for the groundbreaking work done by the clinicians at Erasmus and are committed to the goal of helping patients with this deadly disease,” says Thomas Equels, CEO of Hemispherx.
READ: Hemispherx Biopharma updates terms of $8 million rights offering, says senior management is participating
Recent results from animal studies will be used to help finalize the design of a Phase 2 clinical trial in patients with advanced pancreatic cancer using checkpoint blockade therapies plus Ampligen at the University of Nebraska Medical Center.
Hemispherx is studying the use of Ampligen as a combination therapy for the treatment of multiple cancers at key cancer centers throughout the US.
Headquartered in Ocala, Florida, Hemispherx’s flagship products include Ampligen (rintatolimod), which fights both cancer and chronic fatigue syndrome, and the FDA-approved drug Alferon N Injection, a treatment for genital warts.
Contact Ellen Kelleher at [email protected]